“The shift in Biogen’s strategy concerning Zurzuvae, a drug marketed for postpartum depression, is significantly influenced by the increasingly pivotal role of obstetricians and gynecologists (OB/GYNs) in managing intricate pregnancy-related conditions. This change in strategy was not immediately apparent; initially, Biogen targeted psychiatrists as the primary audience for promoting Zurzuvae. However, the reality of postpartum depression treatment swiftly corrected this approach when prescriptions began to predominantly originate from OB/GYNs, who often serve on the front lines of identifying and treating this condition.
Lawrence Wai, head of Biogen’s U.S. neuropsychiatry franchise, acknowledged this unexpected development. He pointed out that postpartum depression treatment should not be confined to a single specialty but instead should be viewed as an “all of the above” type of disorder. Any medical professional who first identifies the symptoms has a responsibility to intervene. Since many women after birth primarily interact with their OB/GYN, this is typically where the disorder is first discovered.
Wai further emphasized the shared responsibility in treating postpartum depression by referencing a popular meme used by psychiatry educators: three versions of Spiderman standing in a circle, all pointing at each other. He said, “Whether you’re an OB/GYN, women’s health or primary care, you are responsible for treating it, not to point a finger at someone else.” This statement underscores the collaborative, multi-disciplinary nature needed to address postpartum depression effectively.
The poignant anecdote of a patient tragically taking her own life after successful delivery underscores the urgent need for healthcare providers to play a crucial role in supporting maternal mental health postpartum. These instances highlight the severity of conditions like extreme hypertension and gestational diabetes, which can have severe consequences if not managed effectively during pregnancy.
As Biogen and its partner Sage Therapeutics approach two years of marketing Zurzuvae since its approval in August 2023, the focus is on forging collaborations with OB/GYNs. By leveraging the expertise of both parties, innovative approaches can be developed to address maternal health issues. This shift underscores the importance of holistic care that considers not only the physical aspects of pregnancy but also the mental and emotional well-being of patients. It emphasizes the necessity for comprehensive support systems in maternal healthcare, further highlighting the need for an integrated, multi-disciplinary approach in managing postpartum depression and other complex medical conditions related to pregnancy.”
Read more from biospace.com
